MedTrace Logo

Prospective, Multicenter Study of the Efficacy and Tolerance of Tacrolimus on Refractory Nephrotic Syndrome (RNS)

NCT00615667 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2016-04-20

No results posted yet for this study

Summary

Exploring the efficacy and safety of Tacrolimus on refractory nephrotic syndrome ; Acquiring the experience of Tacrolimus on the treatment of refractory nephrotic syndrome in Chinese patients.

Conditions

Interventions

DRUG

tacrolimus (FK506)

Started: 0.05-0.1mg/kg/d,divided into two daily dose at 12hr; the blood level:5-10ng/ml in induction phase;and 4-6ng/ml in maintenance phase;

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Xueqing Yu, MD · Department of Nephrology, 1st Affiliated Hospital, Sun Yat-Sen University

  • Ping Fu, MD · Department of Nephrology, West China Hospital of Sichuan University

  • Yunhua Liao, MD · Department of Nephrology, 1st Affiliated Hospital of Guangxi Medical University

  • Jin li Zhang, MD · Department of nephrology, People's Hospital of Yunnan Province

  • Jian Chen, MD · Department of Nephrology, Fuzhou Military General Hospital

  • Tanqi Lou, MD · Department of Nephrology, 3rd Affiliated Hospital of Sun Yet-Sen University

  • Yaozhong Kong, MD · Department of Nephrology, 1st People's Hospital of Foshan

  • Junzhou Fu, MD · Department of Nephrology,1st People's Hospital of Guangzhou

  • Wei Shi, MD · Department of Nephrology, People's Hospital Guangdong Provincial

  • Zhengrong Liu, MD · Department of Nephrology, Nanfang Hospital of Southern Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
14 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2008-09-30
Completion
2008-09-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00615667 on ClinicalTrials.gov